The Technical Analyst
Select Language :
Aravive Inc [ARAV]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Aravive Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Aravive Inc is listed at the  Exchange

-13.39% $0.0401

America/New_York / 26 jan 2024 @ 16:00


FUNDAMENTALS
MarketCap: 2.95 mill
EPS: -0.760
P/E: -0.0528
Earnings Date: Mar 12, 2024
SharesOutstanding: 73.56 mill
Avg Daily Volume: 2.24 mill
RATING 2024-01-26
S+
Strong Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Strong Buy
DE: Strong Buy
P/E: Strong Buy
Price To Book: Strong Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.0528 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.01x
Company: PE -0.0528 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.0271 - 0.0531

( +/- 32.42%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-04-10 Petrini Maria Carolina Buy 400 000 Nonqualified Stock Option (Right to Buy)
2023-04-10 Petrini Maria Carolina Buy 0
2023-02-01 Mcintyre Gail Frances Buy 700 000 Stock Option (Right to Buy)
2023-02-01 Geller Robert B. Buy 400 000 Stock Option (Right to Buy)
2023-02-01 Howard Rudy Buy 400 000 Stock Option (Right to Buy)
INSIDER POWER
100.00
Last 91 transactions
Buy: 72 486 477 | Sell: 119 333

Forecast: 01:40 - $0.0780

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.0401 (-13.39% )
Volume 4.04 mill
Avg. Vol. 2.24 mill
% of Avg. Vol 180.15 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Aravive Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Aravive Inc

RSI

Intraday RSI14 chart for Aravive Inc

Last 10 Buy & Sell Signals For ARAV

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Aravive Inc

ARAV

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Last 10 Buy Signals

Date Signal @
RBNUSDMar 28 - 21:231.650
ZRXUSDMar 28 - 21:11$1.016
PROUSDMar 28 - 21:08$2.26
LEOUSDMar 28 - 21:086.03
ICPUSDMar 28 - 21:06$18.06
SANTOSUSDMar 28 - 20:587.76
FXSUSDMar 28 - 20:59$7.71
KUBUSDMar 28 - 20:582.77
KCSUSDMar 28 - 20:58$12.06
BCHUSDMar 28 - 21:00$568.09

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.